enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Denosumab - Wikipedia

   en.wikipedia.org/wiki/Denosumab

   Denosumab, sold under the brand name Prolia among others, is a human monoclonal antibody used for the treatment of osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone.

3. List of therapeutic monoclonal antibodies - Wikipedia

   en.wikipedia.org/wiki/List_of_therapeutic...

   Therapeutic, diagnostic and preventive monoclonal antibodies are clones of a single parent cell. When used as drugs, the International Nonproprietary Names (INNs) end in -mab.

4. Generic Product Identifier - Wikipedia

   en.wikipedia.org/wiki/Generic_Product_Identifier

   The Generic Product Identifier (GPI) is a 14-character hierarchical classification system created by Wolters Kluwer's Medi-Span that identifies drugs from their primary therapeutic use down to the unique interchangeable product regardless of manufacturer or package size. The code consists of seven subsets, each providing increasingly more ...

5. Prolia: Is it covered by Medicare?

   www.aol.com/lifestyle/prolia-covered-medicare...

   Prolia (denosumab) is an injectable medication that helps treat osteoporosis. Osteoporosis is a condition that causes the bones to become thin and weak, leading to a higher risk of fractures and ...

6. US FDA adds 'boxed warning' for Amgen's bone loss drug Prolia

   www.aol.com/news/us-fda-adds-boxed-warning...

   Boxed warnings are the strictest warnings issued by the FDA regarding the potential serious side effect from the use of a drug. Prolia, approved in 2010 to treat bone loss in postmenopausal women ...

7. Sandoz Settles Patent Dispute With Amgen Related To Bone ...

   www.aol.com/finance/sandoz-settles-patent...

   Generic and biosimilar manufacturer Sandoz AG (OTC:SDZNY) (OTC:SDZXF) reached an agreement on Tuesday with Amgen Inc (NASDAQ:AMGN) to resolve all patent litigation related to its U.S. denosumab ...

8. Romosozumab - Wikipedia

   en.wikipedia.org/wiki/Romosozumab

   Romosozumab is used for osteoporosis to decrease the risk of fractures. [10] Two trials found that it reduced the rate of vertebral fracture. In one, there was a 73% lower risk of vertebral fracture after one year, and the benefit was maintained after a second year of taking denosumab.

9. Sandoz dials up product launch plans ahead of market debut - AOL

   www.aol.com/news/sandoz-dials-product-launch...

   Sandoz plans to launch at least five additional biologic drugs, its CEO Richard Saynor said, as the generics drugs business of Switzerland's Novartis works to enhance its investor appeal ahead of ...